A pilot study investigating the effects of apixaban in patients with chronic disseminated intravascular coagulation (DIC) - Apixaban for Chronic DIC

akayama Takayuki0 sites5 target enrollmentStarted: March 7, 2019Last updated: October 17, 2023

Conditions

Trial Snapshot

No summary available.

•1) Patients with a diagnosis of DIC on the basis of criteria established by the new criteria for DIC research from the Japanase Society of Hemostasis and Thrombosis (2017 version) .
•2) Patients aged 15 years and over at the time of consent acquisition .
•3) Informed consents are obtained form patients or legal representatives.
•4) Patients with clinical symptons such as thrombocytopenia and/or fibrinogenopenia induced by DIC.

•1 Patients with a history or present illness of severe allergy to a drug
•2 Patients with severe renal disorder (< CLcr 30mL/min)
•3 Patients whom the study drug might induce to bleed
•4 Patients believed to die early even if they recovered from DIC, making it difficult to ensure a sufficient period of administration of the study drug and to obtain data on the efficacy and safety
•5 Pregnant women, nursing mothers or possibly pregnant women
•6 Patients whom the investigator considers to be unsuitable for participation in the study
•7 Patients with severe hepatic disorder (< CLcr 30mL/min)
•8 Patients treated with direct oral anticoagulants

Sponsor

akayama Takayuki